September 20, 2017 8:17 AM ET

Biotechnology

Company Overview of Neurotech Pharmaceuticals, Inc.

Company Overview

Neurotech Pharmaceuticals, Inc., a biotechnology company, develops transformative therapies for chronic eye diseases. Its products are based on encapsulated cell therapy (ECT), which is a genetically engineered ocular implant that enables continuous production of therapeutic proteins to the eye for a period of two years. The company offers NT-503 ECT, which is intended for use in the treatment of neo-vascular age-related macular degeneration; NT-506 ECT, which delivers anti-platelet-derived and anti-vascular endothelial growth factor proteins in a single implant; and NT-501 ECT, which is intended for use in treatment of retinal degenerative diseases. Neurotech Pharmaceuticals, Inc. was forme...

900 Highland Corporate Drive

Building 1

Suite 101

Cumberland, RI 02864

United States

Founded in 1995

Phone:

401-333-3880

Fax:

401-333-3881

Key Executives for Neurotech Pharmaceuticals, Inc.

Executive Chairman
Age: 60
Chief Financial Officer, Chief Operating Officer and Director
Age: 62
Chief Medical Officer
Age: 66
Vice President of Core Technology Development
Vice President of Manufacturing
Compensation as of Fiscal Year 2017.

Neurotech Pharmaceuticals, Inc. Key Developments

Neurotech Pharmaceuticals, Inc. Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia

Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macular Telangiectasia type 2 (MacTel). The multicenter, randomized clinical trial demonstrated a statistically significant reduction in the progressive loss of photoreceptors in treated versus untreated eyes. NT-501 utilizes the Company's proprietary Encapsulated Cell Therapy (ECT) platform that can be customized to deliver specific therapeutic molecules to the back of the eye for retinal disease. The Phase 2 study enrolled 67 patients (99 eyes) at eight sites in the United States and three in Australia. Eligible eyes were randomized to receive either the NT-501 implant containing CNTF or a sham procedure. The primary endpoint, change in the ellipsoid zone from baseline to month 24, was measured by Spectral Domain Optical Coherence Tomography (SD-OCT). An increase in the area of the ellipsoid zone is a measure of disease progression in patients with MacTel and is correlated with loss of photoreceptors leading to visual loss. At 24 months, there was significantly less photoreceptor loss in eyes treated with NT-501 versus sham. The area of ellipsoid zone break increased by 0.213 mm2 in sham eyes compared to 0.148 mm2 in treated eyes. The difference in the increase of the MacTel lesion (0.065 mm2) was statistically significant (p=0.030). The proportion of study eyes with a 35% or more increase from baseline in the ellipsoid zone was significantly reduced in the treated group (p = 0.045) and macular thickness was significantly increased in the treated population when compared to the control group (p=0.007). Secondary clinical outcomes showed reading speed being maintained in the study eyes while deteriorating in the sham eyes (p=0.016). NT-501 was generally well tolerated, consistent with previous studies of NT-501 in retinitis pigmentosa and dry AMD. No participants had the implant removed during the course of the study. The majority of adverse events were related to the surgical procedure. In all cases these surgery-related events were resolved within 3 months.

Neurotech Presents at Leerink Healthcare Summit, Sep-22-2016 11:30 AM

Neurotech Presents at Leerink Healthcare Summit, Sep-22-2016 11:30 AM. Venue: Napa Valley, California, United States. Speakers: James V. Mazzo, Global President of Ophthalmic Medical Devices, ZEISS & Chairman.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Neurotech Pharmaceuticals, Inc., please visit www.neurotechusa.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.